ClinicalTrials.gg
TerminatedNCT00060996Updated Mar 7, 2013

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

A Phase 3 interventional study of Remodulin® (treprostinil sodium) Injection in Critical Limb Ischemia, Peripheral Vascular Disease and Foot Ulcers, sponsored by United Therapeutics. Terminated at 7 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-03-07.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.

Enrollment
47th of 82
30 · median 38
Started
2003
with 2 others
Phase 3
9 of 105
1 open now
Registered
2nd of 105
by date

Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 47th largest by enrollment of the 82 interventional ones that give a count, is one of 3 that started in 2003, is one of 9 in phase 3, and was the 2nd registered.

Chronic Limb-Threatening Ischemia

358 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to determine the effect of Remodulin on wound healing and treadmill walk distance.

03

Conditions studied

  • Critical Limb Ischemia
  • Peripheral Vascular Disease
  • Foot Ulcers
  • Rest Leg Pain

Keywords

  • Critical Limb Ischemia
  • Peripheral Vascular Disease
  • UT-15
  • Remodulin
  • treprostinil
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients with Stage III or IV critical limb ischemia due to documented peripheral arterial disease with no planned interventional vascular procedures

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
30 participants
06

Study locations

7 sites
  • University of South Florida College of Medicine
    Tampa, Florida 33606, United States
  • University of Massachusetts Memorial Health
    Worcester, Massachusetts 01655, United States
  • Minneapolis Heart Institute
    Minneapolis, Minnesota 55407-1139, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Presbyterian Medical Center, Philadelphia Heart Institute
    Philadelphia, Pennsylvania 19104, United States
  • South Carolina Heart Center
    Columbia, South Carolina 29204, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Sep 2004 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2003
First posted
May 20, 2003
Start
Feb 2003
Primary completionActual
Sep 2004
CompletionActual
Sep 2004
Last update
Mar 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00060996
Responsible party
Sponsor
First posted
May 20, 2003
Start date
Feb 2003
Primary completion
Sep 2004
Completion
Sep 2004
Last update
Mar 7, 2013

Study contacts

Michael Wade, PhD
study director · United Therapeutics
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion